Dr. Reddy’s Laboratories Ltd has launched Bupropion HCl extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Wellbutrin® SR (bupropion HCl) Sustained-Release Tablets in the United States market approved by the U.S. Food & Drug Administration (USFDA).
The Wellbutrin® SR brand and generic had U.S. sales of approximately $109.6 million MAT for the most recent twelve months ending in July 2016 according to IMS Health*.
Dr. Reddy’s Buproprion SR tablets are available in 100 mg, 150 mg and 200 mg, in bottle count sizes of 60, 100 and 500.
Wellbutrin® SR is a registered trademark of the GSK group of companies
.png)
